Home LiteratureArticle Details
PMID: 12559039 Published · ppublish English Journal Article Review

The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer.

Breast cancer research : BCR ·Vol. 5 ·No. 1 ·2003-00-00 ·Pages 8-15

Lipkowitz S

Abstract

Aberrant activity of growth factor receptors has been implicated in the pathogenesis of a wide variety of malignancies. The negative regulation of signaling by growth factor receptors is mediated in large part by the ubiquitination, internalization, and degradation of the activated receptor. Over the past few years, considerable insight into the mechanisms that control receptor downregulation has been gained. There are also data suggesting that mutations that lead to inhibition of downregulation of growth factor receptors could play a role in the pathogenesis of cancer. Therapies directed at enhancing the degradation of growth factor receptors offer a promising approach to the treatment of malignancies.

MeSH Terms
Breast Neoplasms/metabolism,pathology Cysteine Endopeptidases/metabolism Female Humans Multienzyme Complexes/metabolism Proteasome Endopeptidase Complex Receptors, Growth Factor/metabolism Signal Transduction/physiology Ubiquitin/metabolism
Chemicals
Multienzyme Complexes Receptors, Growth Factor Ubiquitin Cysteine Endopeptidases Proteasome Endopeptidase Complex
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Lipkowitz Stan
Genetics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, Maryland, USA. Stan_Lipkowitz@nih.gov
References (67)
67 references, click to expand
  1. A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes.
    Proc Natl Acad Sci U S A. 1990 Sep;87(17):6738-42 PMID: 2168557
  2. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells.
    Mol Cell Biol. 1991 Feb;11(2):979-86 PMID: 1671297
  3. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
    Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5867-71 PMID: 1352878
  4. Ubiquitination and endocytosis of plasma membrane proteins: role of Nedd4/Rsp5p family of ubiquitin-protein ligases.
    J Membr Biol. 2000 Jul 1;176(1):1-17 PMID: 10882424
  5. Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins.
    J Biol Chem. 2000 Jul 21;275(29):21850-5 PMID: 10806200
  6. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.
    Cancer Res. 2000 Jul 1;60(13):3384-8 PMID: 10910043
  7. Characterization of the CIN85 adaptor protein and identification of components involved in CIN85 complexes.
    Biochem Biophys Res Commun. 2000 Nov 11;278(1):167-74 PMID: 11071869
  8. SETA is a multifunctional adapter protein with three SH3 domains that binds Grb2, Cbl, and the novel SB1 proteins.
    Cell Signal. 2000 Dec;12(11-12):769-79 PMID: 11152963
  9. Recombinant toxins as novel therapeutic agents.
    Annu Rev Biochem. 1992;61:331-54 PMID: 1497314
  10. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.
    EMBO J. 1994 Oct 3;13(19):4515-23 PMID: 7925293
  11. FMS mutations in patients following cytotoxic therapy for lymphoma.
    Leuk Res. 1995 May;19(5):309-18 PMID: 7769831
  12. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases.
    J Biol Chem. 1995 Jul 14;270(28):16580-7 PMID: 7622464
  13. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired.
    J Biol Chem. 1996 Mar 1;271(9):5251-7 PMID: 8617810
  14. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor.
    EMBO J. 1996 Aug 1;15(15):3806-12 PMID: 8670885
  15. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin.
    J Biol Chem. 1996 Sep 13;271(37):22796-801 PMID: 8798456
  16. Targeted therapy of cancer with recombinant immunotoxins.
    Biochim Biophys Acta. 1997 Oct 24;1333(2):C1-6 PMID: 9395287
  17. Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity.
    Oncogene. 1998 Mar 5;16(9):1209-15 PMID: 9528863
  18. Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells.
    J Biol Chem. 1998 Apr 3;273(14):8323-31 PMID: 9525940
  19. The coding region of the Bloom syndrome BLM gene and of the CBL proto-oncogene is mutated in genetically unstable sporadic gastrointestinal tumors.
    Cancer Res. 1998 Sep 1;58(17):3777-81 PMID: 9731483
  20. Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome.
    J Biol Chem. 2000 Aug 25;275(34):26178-86 PMID: 10816576
  21. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation.
    J Biol Chem. 2000 Aug 25;275(34):26625-31 PMID: 10862618
  22. Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor.
    EMBO J. 1999 Jan 4;18(1):28-36 PMID: 9878047
  23. Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains.
    Biochem J. 1999 Feb 1;337 ( Pt 3):591-7 PMID: 9895306
  24. Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels.
    Trends Cell Biol. 1999 Mar;9(3):107-12 PMID: 10201076
  25. The Doa4 deubiquitinating enzyme is required for ubiquitin homeostasis in yeast.
    Mol Biol Cell. 1999 Aug;10(8):2583-94 PMID: 10436014
  26. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70 PMID: 10482195
  27. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83 PMID: 10482197
  28. Epidermal growth factor pathway substrate 15, Eps15.
    Int J Biochem Cell Biol. 1999 Aug;31(8):805-9 PMID: 10481267
  29. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
    Mol Cell Biol. 1999 Oct;19(10):6845-57 PMID: 10490623
  30. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.
    Clin Cancer Res. 1999 Sep;5(9):2311-5 PMID: 10499598
  31. The caveolae membrane system.
    Annu Rev Biochem. 1998;67:199-225 PMID: 9759488
  32. The ubiquitin system.
    Annu Rev Biochem. 1998;67:425-79 PMID: 9759494
  33. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Clin Cancer Res. 1998 Oct;4(10):2545-50 PMID: 9796989
  34. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Clin Cancer Res. 1995 Aug;1(8):859-64 PMID: 9816055
  35. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.
    Genes Dev. 1998 Dec 1;12(23):3663-74 PMID: 9851973
  36. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.
    Mol Cell. 1999 Dec;4(6):1029-40 PMID: 10635327
  37. Endocytosis and degradation of the growth hormone receptor are proteasome-dependent.
    J Biol Chem. 2000 Jan 21;275(3):1575-80 PMID: 10636847
  38. Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl.
    Biochem Biophys Res Commun. 2000 Feb 16;268(2):321-8 PMID: 10679202
  39. Sorting in the endosomal system in yeast and animal cells.
    Curr Opin Cell Biol. 2000 Aug;12(4):457-66 PMID: 10873832
  40. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.
    J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):97-107 PMID: 10882296
  41. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.
    FEBS Lett. 2001 Feb 16;490(3):142-52 PMID: 11223029
  42. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    N Engl J Med. 2001 Mar 15;344(11):783-92 PMID: 11248153
  43. Themes and variations on ubiquitylation.
    Nat Rev Mol Cell Biol. 2001 Mar;2(3):169-78 PMID: 11265246
  44. Cbl: many adaptations to regulate protein tyrosine kinases.
    Nat Rev Mol Cell Biol. 2001 Apr;2(4):294-307 PMID: 11283727
  45. Oncogenic kinase signalling.
    Nature. 2001 May 17;411(6835):355-65 PMID: 11357143
  46. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.
    J Biol Chem. 2001 Feb 2;276(5):3702-8 PMID: 11071886
  47. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cancer Res. 2001 Jun 15;61(12):4892-900 PMID: 11406568
  48. Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex.
    J Biol Chem. 2001 Jul 20;276(29):27677-84 PMID: 11375397
  49. c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route.
    J Cell Sci. 2001 Jun;114(Pt 11):2167-78 PMID: 11493652
  50. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
    Mol Cell. 2001 Nov;8(5):995-1004 PMID: 11741535
  51. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling.
    EMBO J. 2002 Feb 1;21(3):303-13 PMID: 11823423
  52. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies.
    J Cell Biol. 2002 Mar 4;156(5):843-54 PMID: 11864992
  53. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors.
    Nature. 2002 Mar 14;416(6877):183-7 PMID: 11894095
  54. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met.
    Nature. 2002 Mar 14;416(6877):187-90 PMID: 11894096
  55. A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins.
    Nature. 2002 Mar 28;416(6879):451-5 PMID: 11919637
  56. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
    Trends Mol Med. 2002;8(4 Suppl):S55-61 PMID: 11927289
  57. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
    Leukemia. 2002 Apr;16(4):455-62 PMID: 11960322
  58. c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms.
    J Biol Chem. 2002 Apr 26;277(17):14635-40 PMID: 11847211
  59. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins.
    Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6041-6 PMID: 11983899
  60. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.
    EMBO J. 2002 May 15;21(10):2407-17 PMID: 12006493
  61. Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line.
    Oncogene. 2002 May 23;21(23):3677-87 PMID: 12032836
  62. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold.
    Trends Biochem Sci. 2002 Jul;27(7):368-75 PMID: 12114026
  63. Endocytosis and intracellular sorting of receptor tyrosine kinases.
    Front Biosci. 1998 Jul 26;3:d729-38 PMID: 9671598
  64. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts.
    J Cell Biol. 1976 Oct;71(1):159-71 PMID: 977646
  65. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
    Mol Cell Biol. 1989 Mar;9(3):1165-72 PMID: 2566907
  66. FMS mutations in myelodysplastic, leukemic, and normal subjects.
    Proc Natl Acad Sci U S A. 1990 Feb;87(4):1377-80 PMID: 2406720
  67. Conversion of the lac repressor into an allosterically regulated transcriptional activator for mammalian cells.
    Mol Cell Biol. 1990 Jul;10(7):3343-56 PMID: 2162473
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
DOI
10.1186/bcr541
Email
stan_lipkowitz@nih.gov
Published
2003-00-00
Epub
2002-00-07
Pages
8-15
Language
English
Region
England
NLM ID
100927353
PMCID
PMC154127
Subset
IM
External Links
PubMed source DOI: 10.1186/bcr541 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2